Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02329496
Registration number
NCT02329496
Ethics application status
Date submitted
19/11/2014
Date registered
31/12/2014
Date last updated
24/05/2018
Titles & IDs
Public title
REPRISE Next Generation Delivery System
Query!
Scientific title
REPRISE NGDS: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With the Next Generation Delivery System
Query!
Secondary ID [1]
0
0
S2332
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NGDS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Aortic Stenosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Lotus Valve and LOTUS Edge Valve System
Experimental: Lotus Valve and LOTUS Edge Valve System - Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
Treatment: Devices: Lotus Valve and LOTUS Edge Valve System
Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Technical Success
Query!
Assessment method [1]
0
0
Defined as successful vascular access, delivery, and deployment of the Lotus Valve; successful retrieval with the Lotus Next Generation delivery system; and correct positioning of a single Lotus Valve in the proper anatomical location (reported as percent of subjects implanted with a Lotus Valve). Reported as percent of subjects.
Query!
Timepoint [1]
0
0
Immediately post-procedure (patient discharged from operative room)
Query!
Secondary outcome [1]
0
0
Successful repositioning of the study valve if repositioning is attempted
Query!
Assessment method [1]
0
0
Reported as percent of subjects
Query!
Timepoint [1]
0
0
Immediately post-procedure (patient discharged from operative room)
Query!
Secondary outcome [2]
0
0
Successful retrieval of the study valve if retrieval is attempted
Query!
Assessment method [2]
0
0
Reported as percent of subjects
Query!
Timepoint [2]
0
0
Immediately post-procedure (patient discharged from operative room)
Query!
Secondary outcome [3]
0
0
Severe or moderate paravalvular aortic regurgitation as measured by echocardiography and assessed by an independent core laboratory
Query!
Assessment method [3]
0
0
Reported as percent of subjects
Query!
Timepoint [3]
0
0
At discharge from hospital or at 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [4]
0
0
Mild, trace/trivial, or no paravalvular aortic regurgitation as measured by echocardiography and assessed by an independent core laboratory
Query!
Assessment method [4]
0
0
Reported as percent of subjects
Query!
Timepoint [4]
0
0
At discharge from hospital or at 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [5]
0
0
Mean aortic valve pressure gradient as measured by echocardiography and assessed by an independent core laboratory
Query!
Assessment method [5]
0
0
Reported as mean ± standard deviation; mmHg
Query!
Timepoint [5]
0
0
At discharge from hospital or at 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [6]
0
0
Effective orifice area as measured by echocardiography and assessed by an independent core laboratory
Query!
Assessment method [6]
0
0
Reported as mean ± standard deviation; cm2
Query!
Timepoint [6]
0
0
At discharge from hospital or at 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [7]
0
0
Peak aortic valve pressure gradient as measured by echocardiography and assessed by an independent core laboratory
Query!
Assessment method [7]
0
0
Reported as mean ± standard deviation; mmHg
Query!
Timepoint [7]
0
0
At discharge from hospital or at 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [8]
0
0
Peak aortic velocity as measured by echocardiography and assessed by an independent core laboratory
Query!
Assessment method [8]
0
0
Reported as mean ± standard deviation; m/sec
Query!
Timepoint [8]
0
0
At discharge from hospital or at 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [9]
0
0
Mortality: all-cause, cardiovascular, and non-cardiovascular
Query!
Assessment method [9]
0
0
Reported as percent of subjects
Query!
Timepoint [9]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [10]
0
0
Stroke: disabling and non-disabling
Query!
Assessment method [10]
0
0
Reported as percent of subjects
Query!
Timepoint [10]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [11]
0
0
Myocardial infarction (MI): periprocedural (=72 hours post index procedure) and spontaneous (>72 hours post index procedure)
Query!
Assessment method [11]
0
0
Reported as percent of subjects
Query!
Timepoint [11]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [12]
0
0
Bleeding: life-threatening (or disabling) and major
Query!
Assessment method [12]
0
0
Reported as percent of subjects
Query!
Timepoint [12]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [13]
0
0
Acute kidney injury based on the Acute Kidney Injury Network (AKIN) System Stage 3 (including renal replacement therapy) or Stage 2
Query!
Assessment method [13]
0
0
Reported as percent of subjects
Query!
Timepoint [13]
0
0
=7 days post index procedure
Query!
Secondary outcome [14]
0
0
Major vascular complications major
Query!
Assessment method [14]
0
0
Reported as percent of subjects
Query!
Timepoint [14]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [15]
0
0
Repeat procedure for valve-related dysfunction (surgical or interventional therapy)
Query!
Assessment method [15]
0
0
Reported as percent of subjects
Query!
Timepoint [15]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [16]
0
0
Hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV)
Query!
Assessment method [16]
0
0
Reported as percent of subjects
Query!
Timepoint [16]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [17]
0
0
New permanent pacemaker implantation resulting from new or worsened conduction disturbances
Query!
Assessment method [17]
0
0
Reported as percent of subjects
Query!
Timepoint [17]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [18]
0
0
New onset of atrial fibrillation or atrial flutter
Query!
Assessment method [18]
0
0
Reported as percent of subjects
Query!
Timepoint [18]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [19]
0
0
Coronary obstruction
Query!
Assessment method [19]
0
0
Reported as percent of subjects
Query!
Timepoint [19]
0
0
=72 hours post index procedure
Query!
Secondary outcome [20]
0
0
Ventricular septal perforation
Query!
Assessment method [20]
0
0
Reported as percent of subjects
Query!
Timepoint [20]
0
0
=72 hours post index procedure
Query!
Secondary outcome [21]
0
0
Mitral apparatus damage
Query!
Assessment method [21]
0
0
Reported as percent of subjects
Query!
Timepoint [21]
0
0
=72 hours post index procedure
Query!
Secondary outcome [22]
0
0
Cardiac tamponade
Query!
Assessment method [22]
0
0
Reported as percent of subjects
Query!
Timepoint [22]
0
0
=72 hours post index procedure
Query!
Secondary outcome [23]
0
0
Prosthetic aortic valve malpositioning, including valve migration, valve embolization, or ectopic valve deployment
Query!
Assessment method [23]
0
0
Reported as percent of subjects
Query!
Timepoint [23]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [24]
0
0
Transcatheter aortic valve (TAV)-in-TAV deployment
Query!
Assessment method [24]
0
0
Reported as percent of subjects
Query!
Timepoint [24]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [25]
0
0
Prosthetic aortic valve thrombosis
Query!
Assessment method [25]
0
0
Reported as percent of subjects
Query!
Timepoint [25]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [26]
0
0
Prosthetic aortic valve endocarditis
Query!
Assessment method [26]
0
0
Reported as percent of subjects
Query!
Timepoint [26]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [27]
0
0
Neurological status per modified Rankin Scale score
Query!
Assessment method [27]
0
0
Reported as percent of subjects
Query!
Timepoint [27]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [28]
0
0
Neurological status per National Institutes of Health Stroke Scale
Query!
Assessment method [28]
0
0
Reported as percent of subjects
Query!
Timepoint [28]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Secondary outcome [29]
0
0
Functional Improvement from baseline per NYHA functional classification
Query!
Assessment method [29]
0
0
Reported as percent of subjects
Query!
Timepoint [29]
0
0
At discharge from hospital or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 12 months post procedure
Query!
Eligibility
Key inclusion criteria
1. Subject is =70 years of age
2. Subject has documented calcific native aortic valve stenosis with an initial aortic
valve area (AVA) of =1.0 cm2 (or AVA index of =0.6 cm2/m2) and either a mean pressure
gradient =40 mm Hg or a jet velocity =4 m/s, as measured by echocardiography.
3. Subject has a documented aortic annulus size between =20 and =27.5 mm based on
pre-procedure diagnostic imaging
4. Subject has symptomatic aortic valve stenosis with NYHA Functional Class = II.
5. Subject is considered high risk for surgical valve replacement based on at least one
of the following:
- Society of Thoracic Surgeons (STS) score =8%, and/or
- Agreement by the heart team (which must include an in-person evaluation by an
experienced cardiac surgeon) that subject is at high operative risk of serious
morbidity or mortality with surgical valve replacement.
6. Heart team (which must include an experienced cardiac surgeon) assessment that the
subject is likely to benefit from valve replacement
7. Subject (or legal representative) understands the study requirements and the treatment
procedures, and provides written informed consent.
8. Subject, family member and/or legal representative agree(s) and subject is capable of
returning to the study hospital for all required scheduled follow up visits.
Query!
Minimum age
70
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Subject has a congenital unicuspid or bicuspid aortic valve.
2. Subject with an acute myocardial infarction within 30 days of the index procedure
(defined as Q-wave MI or non-Q-wave MI with total CK elevation = twice normal in the
presence of creatine kinase-myoglobin band (CK-MB) elevation and/or troponin level
elevation).
3. Subject has had a cerebrovascular accident or transient ischemic attack within the
past 6 months, or has any permanent neurologic defect prior to study enrollment.
4. Subject is on dialysis or has serum creatinine level >3.0 mg/dL or 265 µml/L.
5. Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic
ring in any position.
6. Subject has =3+ mitral regurgitation, =3+ aortic regurgitation or =3+ tricuspid
regurgitation (i.e., subject cannot have more than moderate mitral, aortic or
tricuspid regurgitation).
7. Subject has a need for emergency surgery for any reason.
8. Subject has a history of endocarditis within 12 months of index procedure or evidence
of an active systemic infection or sepsis.
9. Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.
10. Subject has Hgb <9 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or
white blood cell count <1,000 cells/mm3.
11. Subject is receiving chronic (=72 hours) anticoagulation therapy (warfarin), and
cannot tolerate concomitant therapy with aspirin or clopidogrel (subjects who require
chronic anticoagulation must additionally be able to be treated with either aspirin or
clopidogrel).*
12. Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3
months, other bleeding diathesis or coagulopathy or will refuse transfusions.
13. Subject has known hypersensitivity to contrast agents that cannot be adequately
pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin,
nickel, titanium, or polyurethanes.
14. Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid
conditions based on the assessment of the investigator at the time of enrollment.
15. Subject has hypertrophic obstructive cardiomyopathy.
16. Subject has any therapeutic invasive cardiac procedure within 30 days prior to the
index procedure (except for balloon aortic valvuloplasty and pacemaker implantation
which are allowed).
17. Subject has untreated coronary artery disease, which in the opinion of the treating
physician, is clinically significant and requires revascularization.
18. Subject has documented left ventricular ejection fraction <30%.
19. Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic
support or mechanical support devices.
20. Subject has severe peripheral vascular disease (including aneurysm defined as maximal
luminal diameter >5 cm or with documented presence of thrombus, marked tortuosity,
narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick [>5
mm] protruding or ulcerated atheroma in the aortic arch) or symptomatic carotid or
vertebral disease.
21. Femoral artery lumen of <6.0 mm for subjects requiring 23 mm valve size or <6.5 mm for
subjects requiring 27 mm valve size, or severe iliofemoral tortuosity or calcification
that would prevent safe placement of the introducer sheath.
22. Current problems with substance abuse (e.g., alcohol, etc.).
23. Subject is participating in another investigational drug or device study that has not
reached its primary endpoint.
24. Subject has untreated conduction system disorder (e.g., Type II second degree
atrioventricular block) that in the opinion of the treating physician is clinically
significant and requires a pacemaker implantation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/12/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/10/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
38
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Prince Charles Hospital - Chermside
Query!
Recruitment hospital [2]
0
0
Monash Heart - Clayton
Query!
Recruitment postcode(s) [1]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boston Scientific Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To confirm the acute performance and safety of the Lotus™ Valve with the Next Generation
Delivery System for transcatheter aortic valve replacement (TAVR) in symptomatic patients
with severe calcific aortic stenosis who are considered high risk for surgical valve
replacement.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02329496
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Robert Gooley, MD
Query!
Address
0
0
Monash
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02329496
Download to PDF